JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $145 from $140 and keeps a Neutral rating on the shares. The firm views the company’s Q2 results as solid but maintains a Neutral rating on valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Strong Financial Performance and Growth Prospects Drive Buy Rating
- Neurocrine’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Commercial Execution and Growth Opportunities
- Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy Rating
- Neurocrine Biosciences Reports Strong Q2 2025 Growth
- Neurocrine’s Strong Growth Potential and Positive Outlook Justify Buy Rating